Last Updated : November 30, 2023
Details
Review Type: Panel
Provisional Funding Algorithm |
|
|---|---|
| Draft Report Posted: | November 30, 2023 |
| Stakeholder Feedback Deadline: | December 07, 2023 |
| Final Report Posted: | January 24,2024 |
Last Updated : January 24, 2024
Details
| Call for patient/clinician input open | November 14, 2023 |
|---|---|
| Call for patient/clinician input closed | January 12, 2024 |
| Clarification: - Patient input submission received from Canadian XLH Network | |
| Submission received | January 02, 2024 |
| Submission accepted | January 16, 2024 |
| Review initiated | January 17, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | April 04, 2024 |
| Deadline for sponsors comments | April 15, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
| Expert committee meeting (initial) | May 22, 2024 |
| Draft recommendation issued to sponsor | June 04, 2024 |
| Draft recommendation posted for stakeholder feedback | June 13, 2024 |
| End of feedback period | June 27, 2024 |
| Clarification: - Reconsideration: minor revisions requested by drug programs - Request for reconsideration accepted - Reconsideration: major revisions requested by drug programs - Request for reconsideration accepted | |
| Expert committee meeting | September 25, 2024 |
| Final recommendation issued to sponsor and drug plans | October 10, 2024 |
| Final recommendation posted | October 29, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | October 25, 2024 |
| CADTH review report(s) posted | February 12, 2025 |
Last Updated : February 12, 2025
Details
Last Updated : November 10, 2023
Details
| Call for patient/clinician input open | November 09, 2023 |
|---|---|
| Call for patient/clinician input closed | January 08, 2024 |
| Call for industry input open | November 09, 2023 |
| Call for industry input closed | January 08, 2024 |
| Submission received | October 24, 2023 |
| Review initiated | October 25, 2023 |
| Expert committee meeting (initial) | May 10, 2024 |
| Draft recommendation posted for stakeholder feedback | June 06, 2024 |
| End of feedback period | June 20, 2024 |
| Final recommendation posted | August 01, 2024 |
| Canada's Drug Agency review report(s) posted | August 01, 2024 |
Last Updated : October 30, 2024
Details
| Call for patient/clinician input open | November 09, 2023 |
|---|---|
| Call for patient/clinician input closed | January 08, 2024 |
| Call for industry input open | November 09, 2023 |
| Call for industry input closed | January 08, 2024 |
| Submission received | October 24, 2023 |
| Review initiated | October 25, 2023 |
| Expert committee meeting (initial) | May 10, 2024 |
| Final recommendation posted | August 01, 2024 |
| Canada's Drug Agency review report(s) posted | August 01, 2024 |
Last Updated : October 30, 2024
Details
| Call for patient/clinician input open | November 08, 2023 |
|---|---|
| Call for patient/clinician input closed | January 08, 2024 |
| Clarification: - Patient input submission received from Schizophrenia Society of Canada | |
| Submission received | December 20, 2023 |
| Submission accepted | January 11, 2024 |
| Review initiated | January 12, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | April 08, 2024 |
| Deadline for sponsors comments | April 17, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
| Expert committee meeting (initial) | May 22, 2024 |
| Clarification: Recommendation deferred to June 26, 2024 CDEC meeting | |
| Draft recommendation issued to sponsor | July 10, 2024 |
| Draft recommendation posted for stakeholder feedback | July 18, 2024 |
| End of feedback period | August 01, 2024 |
| Final recommendation issued to sponsor and drug plans | August 15, 2024 |
| Final recommendation posted | September 03, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | August 29, 2024 |
| CADTH review report(s) posted | January 16, 2025 |
Last Updated : January 17, 2025
Details
| Call for patient/clinician input open | 30-Oct-23 |
|---|---|
| Call for patient/clinician input closed | 22-Dec-23 |
| Clarification: - Patient input submission received from Lung Cancer Canada and the Lung Health Foundation | |
| Submission received | 11-Dec-23 |
| Submission accepted | 02-Jan-24 |
| Clarification: - Additional information has been received and the temporary suspension of the review has been lifted | |
| Review initiated | 03-Jan-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 21-Jun-24 |
| Deadline for sponsors comments | 03-Jul-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 01-Aug-24 |
| Expert committee meeting (initial) | 14-Aug-24 |
| Draft recommendation issued to sponsor | 26-Aug-24 |
| Draft recommendation posted for stakeholder feedback | 05-Sep-24 |
| End of feedback period | 19-Sep-24 |
| Final recommendation issued to sponsor and drug plans | 03-Oct-24 |
| Final recommendation posted | 22-Oct-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 18-Oct-24 |
| CDA-AMC review report(s) posted | 29-Jan-25 |
Last Updated : May 28, 2025
Details
| Call for patient/clinician input open | October 30, 2023 |
|---|---|
| Call for patient/clinician input closed | December 22, 2023 |
| Clarification: - Patient input submission received from the Canadian Migraine Society and Migraine Canada | |
| Submission received | December 21, 2023 |
| Submission accepted | January 12, 2024 |
| Review initiated | January 15, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | April 02, 2024 |
| Deadline for sponsors comments | April 11, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
| Expert committee meeting (initial) | May 22, 2024 |
| Draft recommendation issued to sponsor | June 04, 2024 |
| Draft recommendation posted for stakeholder feedback | June 13, 2024 |
| End of feedback period | June 27, 2024 |
| Clarification: - Reconsideration: minor revisions requested by sponsor - Request for reconsideration not accepted | |
| Final recommendation issued to sponsor and drug plans | July 15, 2024 |
| Final recommendation posted | July 31, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | July 29, 2024 |
| CADTH review report(s) posted | December 13, 2024 |
Last Updated : December 16, 2024
Details
| Call for patient/clinician input open | 26-Oct-23 |
|---|---|
| Call for patient/clinician input closed | 15-Dec-23 |
| Clarification: - Patient input submission received from CCRAN collectively with CCSN & GI Society | |
| Submission received | 07-Dec-23 |
| Submission accepted | 21-Dec-23 |
| Review initiated | 22-Dec-23 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 18-Mar-24 |
| Deadline for sponsors comments | 27-Mar-24 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 25-Apr-24 |
| Expert committee meeting (initial) | 08-May-24 |
| Draft recommendation issued to sponsor | 22-May-24 |
| Draft recommendation posted for stakeholder feedback | 30-May-24 |
| End of feedback period | 13-Jun-24 |
| Clarification: - Reconsideration: minor revisions requested by drug programs - Request for reconsideration accepted | |
| Final recommendation issued to sponsor and drug plans | 11-Jul-24 |
| Final recommendation posted | 29-Jul-24 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 25-Jul-24 |
| Canada's Drug Agency review report(s) posted | 21-Nov-24 |
Last Updated : November 21, 2024